WCN25-3780 DOUBLE ANTIBODY POSITIVE RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS: A CASE SERIES FROM A TERTIARY CARE HOSPITAL IN NEPAL

serious adverse events resulting requiring hospitalization or drug discontinuation.Conclusions: This is the largest real world study till date in IgA nephropathy patients which demonstrates a significant reduction in proteinuria in the cohort with the extended release budesonide (Iganef) with eGFR stabilization at 9 months of therapy.In our study Iganef was beneficial even in pateints with lower grades of proteinuria (<800 mg/g) and advanced stages of CKD ( eGFR <35) which were not evaluated in Nefgan trial.However, a longer follow-up study is needed to confirm its sustained benefit beyond completion of nine months of therapy on both proteinuria reduction and eGFR stabilization.Additionally, Iganef has a promising safety profile, with no serious hospitalizations for infections being reported in our cohort.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.